The effect of NAT2 genotype and gender on the metabolism of caffeine in nonsmoking subjects

British Journal of Clinical Pharmacology

Volumn 49, Issue 3, 2000, Pages 240-243

  Welfare, Mark R ^a,b   Bassendine, Margaret F ^a   Daly, Ann K ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NORTH TYNESIDE GENERAL HOSPITAL   (United Kingdom)

Author keywords

Caffeine; CYP1A2; NAT2

Indexed keywords

ACYLTRANSFERASE; CAFFEINE;

ARTICLE; CLINICAL TRIAL; DRUG ACETYLATION; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME ACTIVITY; FEMALE; GENDER; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADOLESCENT; ADULT; ARYLAMINE N-ACETYLTRANSFERASE; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; CYTOCHROME P-450 CYP1A2; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SEX CHARACTERISTICS; SMOKING;

EID: 0034014805     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2000.00130.x     Document Type: Article

References (11)

1. 1 Lang NP, Butler MA, Massengill J, et al. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer and polyps. Cancer Epidemiol Biomarkers Prevention 1994; 3: 675-682.
2. 2 Catteau A, Bechtel YC, Poisson N, Bechtel PR, Bonaiti-Pellie C. A population and family study of CYP1A2 using caffeine urinary metabolites. Eur J Clin Pharmacol 1995; 47: 423-430.
3. 3 Nakajima M, Yokoi T, Mizutani M, Shin S, Kadlubar FF, Kamataki T. Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomarkers Prevention 1994; 3: 413-421.
4. 4 Rostami-Hodjegan A, Nurminen S, Jackson PR, Tucker GT. Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics 1996; 6: 121-149.
5. 5 Welfare MR, Aitkin M, Bassendine MF, Daly AK. Detailed modelling of caffeine metabolism and examination of the CYP1A2 gene: lack of a polymorphism in CYP1A2 in Caucasians. Pharmacogenetics 1999; 9: 367-375.
6. 6 Butler MA, Lang NP, Young JF, et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992; 2: 116-127.
7. 7 Welfare MR, Cooper J, Bassendine MF, Daly AK. Relationship between acetylator status, smoking, diet and colorectal cancer risk in the north-east of England. Carcinogenesis, 1997; 18: 1351-1354.
8. 8 NAT. nomenclature website at: http://www.louisville.edu/ medschool/pharmacology/NAT.html.
9. 9 Hickman D, Sim E. N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans. Biochem Pharmacol 1991; 42: 1015-1019.
10. 10 Daly LE, Bourke GJ, McGilvray J, eds. Interpretations, uses of medical statistics. Blackwell. Oxford, 1991.
11. 11 Fuhr U, Rost KL. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics 1994; 4: 109-116.